Join to View Full Profile
1305 York AveFl 12New York, NY 10021
Phone+1 646-962-6200
Dr. Mehta is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityResidency, Internal Medicine, 2011 - 2014
Topiwala National Medical CollegeClass of 2007
University at BuffaloFellowship, Hematology and Medical Oncology
Certifications & Licensure
NY State Medical License 2017 - 2026
FL State Medical License 2017 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Start of enrollment: 2018 Dec 20
- Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) Start of enrollment: 2019 Jul 22
Roles: Principal Investigator, Contact
- Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors Start of enrollment: 2023 Jul 13
Roles: Principal Investigator
Publications & Presentations
PubMed
- ASO Visual Abstract: Clinical and Pathologic Response to Neoadjuvant Immunotherapy in DNA Mismatch Repair Protein-Deficient Gastroesophageal Cancers.Adrienne B Shannon, Rutika Mehta, Shaffer R Mok, Gregory Y Lauwers, Jobelle J A R Baldonado
Annals of Surgical Oncology. 2025-01-01 - 1 citationsDetecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection.James Yu, Aiwu Ruth He, Mahmoud Ouf, Rutika Mehta, Daniel A Anaya
JCO Precision Oncology. 2025-01-01 - 1 citationsClinical and Pathologic Response to Neoadjuvant Immunotherapy in DNA Mismatch Repair Protein-Deficient Gastroesophageal Cancers.Adrienne B Shannon, Rutika Mehta, Shaffer R Mok, Gregory Y Lauwers, Jobelle J A R Baldonado
Annals of Surgical Oncology. 2024-12-01
Press Mentions
Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse GliomaApril 23rd, 2025- New Signateratm MRD Data in Gastrointestinal Cancers to Be Presented at the ASCO GI Symposium 2023January 19th, 2023
- New Signatera™ MRD Data in Gastrointestinal Cancers to Be Presented at the ASCO GI Symposium 2023January 19th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
